



## Post-Acute-COVID-19-Illness Cardiovascular Sequelae

Cheepsattayakorn A<sup>1,3\*</sup> Cheepsattayakorn R<sup>2</sup> and Siriwanarangsun P<sup>3</sup>

<sup>1</sup>10<sup>th</sup> Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand

<sup>2</sup>Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

<sup>3</sup>Faculty of Medicine, Western University, Pathumtani Province, Thailand

**\*Corresponding author:** Attapon Cheepsattayakorn, 10<sup>th</sup> Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road, Changklan Muang, Chiang Mai, 50100, Thailand, Tel: 66 53 140767; 66 53 276364; Fax: 66 53 140773; 66 53 273590; Email: Attapon1958@gmail.com

### Editorial

Volume 5 Issue 4

Received Date: June 17, 2021

Published Date: July 13, 2021

DOI: 10.23880/mjccs-16000296

### Editorial

At 60 days of the following-up, chest pain was present around 20 % of the COVID-19 survivors, whereas at 6 months following-up in the post-acute-COVID-19 Chinese study revealed ongoing chest pain and palpitations in 5 % and 9 % of the COVID-19 survivors, respectively [1-3]. Ongoing myocardial inflammation may occur at the rates as high as 60 % more than two months after the diagnosis by MRI [4]. The perpetuated mechanisms in post-acute-COVID-19-illness cardiovascular sequelae include SARS-CoV-2 (COVID-19) viral invasion, the immunologic response and inflammation affecting the structural integrity of the cardiac conduction system, pericardium, and myocardium, and downregulation of ACE 2. Autopsy studies in 39 COVID-19 cases (62.5 %) revealed SARS-CoV-2 (COVID-19) viral particles in the cardiac tissues that may contribute to the cardiomyocyte death and fibro-fatty displacement of desmosomal proteins that is critical for cell-to-cell adherence [5-7]. Persistently increased cardiometabolic demand may be occur in recovered COVID-19 patients that may be related to decreased cardiac reserve, dysregulation of the renin-angiotensin-aldosterone system (RAAS) [8]. SARS-CoV-2 (COVID-19) can induce heightened catecholaminergic state due to cytokine storming from cytokines, such as IL-1, IL-6, and TNF- $\alpha$ , that can prolong ventricular action potentials by modulating cardiomyocyte ion channel expression, in addition to the induction of resultant cardiomyopathy from SARS-CoV-2 (COVID-19) infection, and myocardial scarring or fibrosis that can contribute to re-entrant cardiac arrhythmias [9,10]. After SARS-CoV-2 (COVID-19) illness, autonomic dysfunction can result in inappropriate sinus tachycardia and postural orthostatic tachycardia syndrome, that has been demonstrated as a resulting adrenergic modulation [11,12]. Abstinence from aerobic activities or competitive sports

for 3-6 months until resolution of myocardial inflammation by normalization of the troponin levels or cardiac MRI and serial echocardiogram, electrocardiogram, and cardiac MRI may be considered in competitive athletes with post-acute-COVID-19-related cardiovascular complications and in those with persistent cardiac symptoms [13-16]. In a previously retrospective study among 3,080 COVID-19 patients revealed that withdrawal of cardiac-guidelines-directed medical treatment was related to higher mortality in the acute to post-acute-COVID-19 illness phases [17]. Potential harmfulness may be occurred in the abrupt cessation of the use of RAAS inhibitors [18]. A low-dose beta blocker for decreasing adrenergic activity and heart rate management and anti-arrhythmic drugs (such as amiodarone) is recommended with attention in post-acute-COVID-19-illness patients with postural orthostatic tachycardia syndrome and with pulmonary fibrotic changes following COVID-19 illness, respectively [19,20].

In conclusion, more follow-up is needed to determine risk-over-time resolution, particularly cardiovascular risk in patients with pre-existing conditions due to sustained- and increased-clinical-sequelae risk is frequently identified from 4 weeks to 4 months after the acute-COVID-19- illness phase.

### References

1. Carfi A, Bernabei R, Landi F (2020) Persistent symptoms in patients after acute COVID-19. *JAMA* 324 (6): 603-605.
2. Carvalho-Schneider C, Laurent E, Lemaigen A, Beaufils E, Bourbao-Tournois C, et al. (2021) Follow-up of adults with noncritical COVID-19 two months after symptom onset. *Clin Microbiol Infect* 27(2): 258-263.

3. Huang C, Huang L, Wang Y, Li X, Ren L, et al. (2021) 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet* 397(10270): 220-232.
4. Puntmann VO, Carerj ML, Wteters I, Fahim M, Arendt C, et al. (2020) Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). *JAMA Cardiol* 5(11): 1265-1273.
5. Lindner D, Fitzek A, Bräuninger H, Aleshcheva G, Edler C, et al. (2020) Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. *JAMA Cardiol* 5(11): 1281-1285.
6. Gemayel C, Pelliccia A, Thompson PD (2001) Arrhythmogenic right ventricular cardiomyopathy. *J Am Coll Cardiol* 38(7): 1773-1781.
7. Siripanthong B, Nazarian S, Muser D, Deo R, Santangeli P, et al. (2020) Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guidelines for diagnosis and management. *Heart Rhythm* 17(9): 1463-1471.
8. Wu Q, Zhou L, Sun X, Yan Z, Hu C, et al. (2017) Altered lipid metabolism in recovered SARS patients twelve years after infection. *Sci Rep* 7(1): 9110.
9. Lazzarini PE, Laghi-Pasini F, Boutjdir M, Capecchi PL (2019) Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies. *Nat Rev Immunol* 19(1): 63-64.
10. Liu PP, Blet A, Smyth D, Li H (2020) The science underlying COVID-19: implications for the cardiovascular system. *Circulation* 142(1): 68-78.
11. Agarwal AK, Garg R, Ritch A, Sarkar P (2007) Postural orthostatic tachycardia syndrome. *Postgrad Med J* 83(981): 478-480.
12. Lau ST, Yu WC, Mok NS, Tsui PT, Tong WL, et al. (2005) Tachycardia amongst subjects recovering from severe acute respiratory syndrome (SARS). *Int J Cardiol* 100(1): 167-169.
13. Hendren NS, Drazner MH, Bozkurt B, Cooper LT Jr (2020) Description and proposed management of the acute COVID-19 cardiovascular syndrome. *Circulation* 141(23): 1903-1914.
14. Maron BJ, et al. (2015) Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies: a scientific statement from the American Heart Association and American College of Cardiology. *J Am Coll Cardiol* 66: 2362-2371.
15. George PM, Barratt SL, Condliffe R, Desai SR, Devaraj A, et al. (2020) Respiratory follow-up of patients with COVID-19 pneumonia. *Thorax* 75(11): 1009-1016.
16. Desai AD, Boursiquot BC, Melki L, Wan EY (2020) Management of arrhythmias associated with COVID-19. *Curr Cardiol Rep* 23(1): 2.
17. Rey JR, Caro-Codón J, Rosillo SO, Iniesta AM, Castrejón-Castrejón S, et al. (2020) Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. *Eur J Heart Fail* 22(12): 2205-2215.
18. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, et al. (2020) Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. *N Engl J Med* 382: 1653-1659.
19. Raj SR, Black BK, Biaggioni I, Paranjape SY, Ramirez M, et al. (2009) Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. *Circulation* 120(9): 725-734.
20. Kociol RD, Cooper LT, Fang JC, Moslehi JJ, Pang PS, et al. (2020) Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association. *Circulation* 141(6): e69-e92.

